EntryPoint Capital LLC Makes New Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX)

EntryPoint Capital LLC acquired a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 20,600 shares of the company’s stock, valued at approximately $359,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in TVTX. R Squared Ltd bought a new position in Travere Therapeutics during the 4th quarter valued at $53,000. Quarry LP bought a new position in Travere Therapeutics in the 3rd quarter valued at $105,000. Victory Capital Management Inc. bought a new position in Travere Therapeutics during the fourth quarter valued at about $182,000. Baader Bank Aktiengesellschaft purchased a new stake in Travere Therapeutics during the fourth quarter worth about $192,000. Finally, Entropy Technologies LP bought a new stake in Travere Therapeutics in the fourth quarter worth about $214,000.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on TVTX. Evercore ISI increased their target price on shares of Travere Therapeutics from $33.00 to $45.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. HC Wainwright raised their target price on Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Wednesday, January 15th. Canaccord Genuity Group upped their price target on Travere Therapeutics from $22.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, February 12th. Citigroup lifted their price objective on Travere Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Monday, February 24th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Travere Therapeutics in a report on Friday, February 21st. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, Travere Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $30.62.

Insider Buying and Selling

In other news, SVP William E. Rote sold 2,437 shares of the business’s stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $19.46, for a total transaction of $47,424.02. Following the completion of the transaction, the senior vice president now owns 83,170 shares of the company’s stock, valued at approximately $1,618,488.20. The trade was a 2.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Peter Heerma sold 1,584 shares of the firm’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $18.94, for a total transaction of $30,000.96. Following the completion of the sale, the insider now directly owns 106,374 shares in the company, valued at $2,014,723.56. This represents a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 191,335 shares of company stock worth $4,194,712. Corporate insiders own 3.75% of the company’s stock.

Travere Therapeutics Trading Down 1.0 %

Shares of TVTX opened at $20.79 on Thursday. Travere Therapeutics, Inc. has a twelve month low of $5.12 and a twelve month high of $25.29. The stock has a market cap of $1.84 billion, a PE ratio of -5.07 and a beta of 0.75. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. The business’s 50-day moving average price is $20.69 and its 200-day moving average price is $18.39.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.15). The firm had revenue of $74.79 million during the quarter, compared to analysts’ expectations of $72.38 million. Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. On average, equities analysts forecast that Travere Therapeutics, Inc. will post -1.4 EPS for the current fiscal year.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.